A 2.6% reduction in hip bone mineral density and a 2.1% reduction at the lumbar spine in 52 weeks (Hansen et al., 2024), combined with up to 10.9% lean mass loss over 72 weeks (Look et al., 2025), means that patients on GLP-1 therapy need a comprehensive musculoskeletal protection plan from day one
Dismiss this notification PatientsLikeMe would like to remind you that your browser is out of date and many features of the website may not function as expected
Among people eligible for treatment, 33.1% (95% CI, 31.4-34.8), 28.1% (95% CI, 26.4-29.8) and 26.2% (95% CI, 24.6-27.9) met the exclusion criteria for tirzepatide, liraglutide and semaglutide, respectively
Next, side effects
The Company will retain Your Personal Data only for as long as is necessary for the purposes set out in this Privacy Policy
While individual results may vary, the effects of Endolift can last for several years